Startseite Radioiodination of olmesartan medoxomil and biological evaluation of the product as a tracer for cardiac imaging
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Radioiodination of olmesartan medoxomil and biological evaluation of the product as a tracer for cardiac imaging

  • M. H. Sanad EMAIL logo , Ebtisam. A. Marzook und Safaa B. Challan
Veröffentlicht/Copyright: 14. November 2017

Abstract

The present study is oriented to synthesis of radioiodinated olmesartan medoxomil (OM) for potential cardiac imaging. Olmesartan medoxomil has been labeled with [125/131I] using chloramine-T (Ch-T) as an oxidizing agent. The key effective factors such as amount of oxidizing agent, amount of substrate, pH, reaction temperature and reaction time, have been systematically studied to get high radiochemical yield of the [125I]olmesartan medoxomil reaching values of 98.5%. The labeled compound was separated and purified using thin layer chromatography (TLC), paper electrophoresis and high performance liquid chromatography (HPLC). The biological distribution indicates the suitability of [125I]olmesartan medoxomil as a novel tracer to image heart with high heart/blood ratio within 30 min which was detected by gamma camera.

References

1. Nicholls, M. G., Richards, A. M., Agarwal, M.: The importance of the renin-angiotensin system in cardiovascular disease. J. Hum. Hypertens. 12, 295 (1998).10.1038/sj.jhh.1000638Suche in Google Scholar PubMed

2. Balt, J. C., Mathy, M. J., Pfaffendorf, M., van Zwieten, P. A.: Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan. J. Hypertens. 19(12), 2241 (2001).10.1097/00004872-200112000-00018Suche in Google Scholar PubMed

3. Kenakin, T.: Competitive antagonism. In: C. Boselli (Ed.), Pharmacologic Analysis of Drug-Receptor Interaction. 3rd ed. Philadelphia, Lippincot & Raven Publishers. 331 (1997).Suche in Google Scholar

4. Skugor, M.: Thyroid Disorders. A Cleveland Clinic Guide. Cleveland Clinic Press, The Amazon Book Review, p. 82. ISBN 978-1-59624-021-6. (2006).Suche in Google Scholar

5. Robbins, J., Schneider, A. B.: Thyroid cancer following exposure to radioactive iodine. Rev. Endocr. Metab. Disord. 1(3), 197 (2000).10.1023/A:1010031115233Suche in Google Scholar

6. Narra, V. R., Howell, R. W., Harapanhalli, R. S., Sastry, K. S., Rao, D. V.: Radiotoxicity of some iodine-123, iodine-125 and iodine-131-labeled compounds in mouse testes: implications for radiopharmaceutical design. J. Nucl. Med. 33(12), 2196 (1992).Suche in Google Scholar

7. Sanad, M. H., Sallam, Kh. M., Marzook, F. A., Abd-Elhaliem, S. M.: Radioiodination and biological evaluation of candesartan as a tracer for cardiovascular disorder detection J. Label Compd. Radiopharm. 59, 484 (2016).10.1002/jlcr.3435Suche in Google Scholar PubMed

8. Liederer, B. M.: Case study: Olmesartan Medoxomil: a prodrug of olmesartan. In: V. J. Stella, R. T. Borchardt, M. J. Hageman, R. Oliyai, H. Maag, J. W. Tilley (Eds.), Prodrugs. Biotechnology: Pharmaceutical Aspects, vol V. Springer, New York, NY (2007).10.1007/978-0-387-49785-3_48Suche in Google Scholar

9. Hans, R. B.: Olmesartan medoxomil current status of its use in monotherapy. Vasc. Health Risk Mangement. 2(4), 327 (2006).10.2147/vhrm.2006.2.4.327Suche in Google Scholar PubMed PubMed Central

10. Ball, K. J., Williams, P. A., Stumpe, K. O.: Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens 19(Suppl. 1), 49 (2001).10.1097/00004872-200106001-00007Suche in Google Scholar PubMed

11. Chrysant, S. G., Marbury, T. C., Robinson, T. D.: Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to moderate hypertension. J. Hum. Hypertens. 17, 425 (2003).10.1038/sj.jhh.1001577Suche in Google Scholar PubMed

12. Gardner, S. F., Franks, A. M.: Olmesartan medoxomil: the seventh angiotensin receptor antagonist. Ann. Pharmacother. 37, 99 (2003).10.1345/aph.1C197Suche in Google Scholar PubMed

13. Benicar (Olmesartan medoxomil) Drug Information: Clinical Pharmacology – Prescribing Information at RxList.” RxList. 27 June (2014). Web. 24 Apr. (2015).Suche in Google Scholar

14. Huttunen, K. M., Raunio, H., Rautio, J.: Prodrugs – from serendipity to rational design. Pharmacol. Rev. 63, 750 (2011).10.1124/pr.110.003459Suche in Google Scholar PubMed

15. Nandini, R. P., Seema, S. S.: Development and validation of new RP-HPLC method for determining impurity profiling in olmesartan medoxomil drug as well as in tablet dosage form. Der. Pharma. Chemica. 5(4), 274 (2013).Suche in Google Scholar

16. Mohammad, A. K., Abolfazl, H.: An easy, safe and simple method for the iodination of heterocyclic compounds in water. Iran J. Org. Chem. 4, 270 (2009).Suche in Google Scholar

17. Abolfazl, H., Mohammad, A. K., Masoumeh, H., Mahmoud, T. A.: A simple method for iodination of heterocyclic compounds using HIO4/NaCl/silica gel/H2SO4 in water. Monatsh Chem. 143, 619 (2012).10.1007/s00706-011-0611-6Suche in Google Scholar

18. Sanad, M. H., Shweeta, H. A.: Preparation and bio-evaluation of 99mTc-carbonyl complex of ursodeoxycholic acid for heptobiliary imaging. J. Mol. Imag. Dynamic. 5, 1 (2015).Suche in Google Scholar

19. Sanad, M. H.: Labeling of Omeprazole with technetium-99m for diagnosis of stomach. Radiochemistry 55(6), 605 (2013).10.1134/S1066362213060076Suche in Google Scholar

20. Ramalingaiah, H., Jagadeesh, R. V., Puttaswamy, M.: Os (VIII)-catalyzed and uncatalyzed oxidation of biotin by chloramine-T in alkaline medium: comparative mechanistic aspects and kinetic modeling. J. Mol. Cat. A: Chem. 265(1–2), 70 (2007).10.1016/j.molcata.2006.09.047Suche in Google Scholar

21. Siddiqui, N., Husain, A., Chaudhry, L., Alam, M., Mitra, M., Bhasin, P.: Pharmacological and pharmaceutical profile of valsartan: a review. J. Appl. Pharm. Sci. 1(4), 12 (2011).Suche in Google Scholar

22. Kuchar, M., Oliveira, M. C., Gano, L., Santos, I., Kniess, T.: Radioiodinated sunitinib as a potential radiotracer for imaging angiogenesis-radiosynthesis and first radiopharmacological evaluation of 5-[125I]Iodo-sunitinib. Bioorg. Med. Chem. Lett. 22(8), 2850 (2012).10.1016/j.bmcl.2012.02.068Suche in Google Scholar

23. Abi-Dargham, A., Zea-Ponce, Y., Terriere, D., Al-Tikriti, M., Baldwin, R. M., Hoffer, P., Charney, D., Leysen, J. E., Laruelle, M., Mertens, J., Innis, R. B.: Preclinical evaluation of [123I] R93274 as a SPECT radiotracer for imaging 5-HT2A receptors. Eur. J. Pharmacol. 321(3), 285 (1997).10.1016/S0014-2999(96)00906-5Suche in Google Scholar

24. Attila, V., Sandor, N., Zoltan, K., Rezso, G. L., Rösch, F.: Handbook of Nuclear Chemistry, 2nd ed. Springer, New York (2011).Suche in Google Scholar

25. Sanad, M. H., Talaat, H. M.: Radioiodination and biological evaluation of rabeprazole as a peptic ulcer localization radiotracer. Radiochemistry 59(3), 307 (2017).10.1134/S1066362217030158Suche in Google Scholar

26. Sanad, M. H.: Labeling and biological evaluation of 99mTc-azithromycin for infective inflammation diagnosis. Radiochemistry 55(5), 539 (2013).10.1134/S1066362213050159Suche in Google Scholar

27. Sanad, M. H., Abdel-Ghaney, I. Y.: Synthesis of 99mTc-erythromycin complex as a model for infection sites imaging. Radiochemistry 55(4), 418 (2013).10.1134/S1066362213040139Suche in Google Scholar

28. Sanad, M. H.: Novel radiochemical and biological characterization of 99mT-histamine as a model for brain imaging. J. Anal. Sci. Technol. 5, 23 (2014).10.1186/s40543-014-0023-4Suche in Google Scholar

Received: 2017-5-29
Accepted: 2017-9-25
Published Online: 2017-11-14
Published in Print: 2018-3-28

©2018 Walter de Gruyter GmbH, Berlin/Boston

Heruntergeladen am 21.10.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ract-2017-2830/html?lang=de
Button zum nach oben scrollen